Sea snake cathelicidin (Hc-cath) exerts a protective effect in mouse models of lung inflammation and infection by Carlile, Simon R. et al.
Sea snake cathelicidin (Hc-cath) exerts a protective effect in mouse
models of lung inflammation and infection
Carlile, S. R., Shiels, J., Kerrigan, L., Delaney, R., Megaw, J., Gilmore, B. F., ... Taggart, C. C. (2019). Sea
snake cathelicidin (Hc-cath) exerts a protective effect in mouse models of lung inflammation and infection.
Scientific Reports, 9, [6071]. https://doi.org/10.1038/s41598-019-42537-8
Published in:
Scientific Reports
Document Version:
Publisher's PDF, also known as Version of record
Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal
Publisher rights
© 2019 The Authors.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and
indicate if changes were made. Te images or other third party material in this
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the
material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation
or exceeds the permitted use, you will need to obtain permission directly from the
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other
copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated
with these rights.
Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to
ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the
Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
Download date:01. Jun. 2019
1Scientific RepoRts |          (2019) 9:6071  | https://doi.org/10.1038/s41598-019-42537-8
www.nature.com/scientificreports
sea snake cathelicidin (Hc-cath) 
exerts a protective effect in mouse 
models of lung inflammation and 
infection
Simon R. Carlile1, Jenna shiels1,2, Lauren Kerrigan1, Rebecca Delaney1, Julianne Megaw3, 
Brendan F. Gilmore3, sinéad Weldon1, John P. Dalton2 & Clifford C. Taggart1
We investigated the anti-inflammatory and antibacterial activities of Hc-cath, a cathelicidin peptide 
derived from the venom of the sea snake, Hydrophis cyanocyntus, using in vivo models of inflammation 
and infection. Hc-cath function was evaluated in in vitro, in vivo in the wax moth, Galleria mellonella, 
and in mouse models of intraperitoneal and respiratory Pseudomonas aeruginosa infection. Hc-Cath 
downregulated LPS-induced pro-inflammatory responses in macrophages and significantly improved 
the survival of P. aeruginosa infected G. mellonella over a 5-day period. We also demonstrated, for the 
first time, that Hc-cath can modulate inflammation in a mouse model of LPS-induced lung inflammation 
by significantly reducing the release of the pro-inflammatory cytokine and neutrophil chemoattractant, 
KC, resulting in reduced cellular infiltration into the lungs. Moreover, Hc-cath treatment significantly 
reduced the bacterial load and inflammation in mouse models of P. aeruginosa intraperitoneal and 
respiratory infection. The effect of Hc-cath in our studies highlights the potential to develop this peptide 
as a candidate for therapeutic development.
Respiratory infections represent a major clinical burden globally and have major implications for patients with 
underlying health conditions such as cystic fibrosis (CF), where bacterial infection can exacerbate pre-existing 
inflammation. Pseudomonas aeruginosa infection is particularly difficult to treat in CF patients, due to its ability 
to form biofilms with antibiotic tolerant persister cells, in addition to the bacteria’s ability to acquire antibiotic 
resistance1. The World health organisation (WHO) have adopted a five-point plan to combat the rise of antibiotic 
resistance including the development of new classes of antibiotics2.
Antimicrobial peptides represent a largely untapped resource of new antibiotic agents that could supplement 
current antibiotics. This study focuses on a group of antimicrobial proteins known as cathelicidins. The proteins 
in this family are grouped on the basis of their shared structure consisting of a pro-form conjugated to a con-
served cathelin domain, which is cleaved to release an active C-terminal peptide3. The only known human cathel-
icidin, CAP18, is a host defense protein secreted predominantly by neutrophils. C-terminal cleavage releases 
a 37-amino acid peptide, LL-37, which plays an important role in the innate immune system. LL-37 displays a 
broad range of antimicrobial activities including antifungal, antiviral and antibacterial activity4. Bacteria such as 
Neisseria gonorrhoea5 and Shigella6 can downregulate the expression of LL-37, increasing their infectivity. The 
absence of LL-37 in the neutrophils of patients with Morbus Kostmann syndrome leads to increased rates of 
periodontitis7. The antimicrobial activity of LL-37 is impaired in CF patients due to the reduced airway pH8. In 
addition, LL-37 activity can be affected by binding to DNA and glycosaminoglycans9 or from degradation by 
proteases in CF sputum10.
Cathelicidins are also found in the venom of various snakes. Hc-cath, a cathelicidin peptide derived from the 
venom of the sea snake Hydrophis cyanocintus, is of particular interest as it has been recently shown to display 
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a broad range of antibiotic activity against clinical bacterial isolates11. Given our interest in developing new 
antibiotic treatments for CF patients, in this study we assessed the ability of Hc-cath to alleviate infection and 
inflammation in mouse models of infection with a view to evaluating this peptide as a candidate for therapeutic 
application.
Results
Sequence and physiochemical properties of Hc-cath. The PSIPRED server and HeliQuest (www.
expasy.org) predicted that Hc-cath has the capacity to form an alpha-helical structure, which is consistent with 
earlier reports11. HeliQuest was used to model the alpha-helical structure of Hc-cath demonstrating that Hc-cath 
displayed a hydrophobic moment of 0.425 and an overall charge of +12 (Fig. 1a). Hc-cath also forms an amphi-
pathic helix with a high concentration of positively-charged residues on the polar face, the amphipathic helix is 
disrupted by the presence of a proline residue that is followed by a C-terminal disordered region (PRLIGLSTLL 
in Hc-Cath) (Fig. 1b).
Hc-cath reduces LPS-induced inflammatory responses by macrophages. Hc-cath displayed lim-
ited cytotoxicity (Fig. 2a) towards macrophages. We therefore assessed the ability of the peptide to downregulate 
LPS-induced cytokine responses at concentrations of 0.28 μM and 1.34 μM. At these concentrations, Hc-cath 
(Fig. 2b,c) significantly reduced the release of LPS-induced IL-6 and IL-8 confirming the ability of the peptide to 
limit LPS-induced inflammation.
Hc-cath displays antimicrobial activity against lung relevant pathogens. We assessed the anti-
microbial activity of Hc-cath against two lung-relevant pathogens, P. aeruginosa and S. aureus. Hc-cath demon-
strated antimicrobial activity against both bacteria (Fig. 3a). Calculations of minimum inhibitory concentrations 
(MIC) revealed that Hc-cath was more potent against P. aeruginosa (Fig. 3b) compared to S. aureus (Fig. 3c)
We also investigated the efficacy of the peptide in an in vivo model of wax moth infection. G. mellonella were 
infected with S. aureus (Fig. 3d) or P. aeruginosa (Fig. 3e) before treatment with Hc-cath and survival assessed 
over a 5-day period. Hc-Cath did not influence the survival of S. aureus infected Galleria (Fig. 3d) compared to 
infection alone. G. mellonella were more sensitive to P. aeruginosa infection, as has been reported by others12, with 
90% of Galleria succumbing to infection by day 5. However a significant improvement was observed in Galleria 
receiving Hc-cath (Fig. 3e).
Figure 1. Analysis of Hc-cath primary and secondary structure. (a) Hc-cath hydrophobic moment and net 
charge. (b) Helical wheel projections demonstrate that the sequences shown in b possess distinct amphipathic 
structures with hydrophobic residues (yellow) collecting on one face of the helices and charged residues (blue) 
collecting on the opposite side.
Figure 2. Hc-cath limits an LPS induced inflammatory response from macrophages. THP-1 macrophages 
were stimulated with increasing concentrations of Hc-cath (a) (0.28 µM, 2.80 µM or 13.78 µM) or staurosporine 
or left untreated (un). Viability was determined after 16 hr. (b,c) ELISA analysis of IL-8 and IL-6 release from 
differentiated THP1 macrophages 16 hr after stimulation with Pseudomonas LPS (100 ng/ml) in combination 
with 0.28 µM or 1.34 µM Hc-cath. Data are presented as mean ± SEM. Means between groups (untreated vs LPS 
and LPS versus LPS + Hc-cath) were compared by Mann Whitney t-test. *Indicates P < 0.05.
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Hc-cath reduces the inflammatory burden in a mouse model of LPS induced acute lung inflam-
mation. Given the efficacy of Hc-cath in limiting LPS-induced inflammation in vitro (Fig. 2a–c), we evaluated 
the effects in an in vivo murine model of lung inflammation. As expected, a significant increase in bronchoalveolar 
lavage fluid (BALF) total cell counts was observed following LPS challenge (Fig. 4a), indicating the infiltration of 
immune cells into the lungs. This increase in total cells was significantly reduced in mice that received prior treat-
ment with Hc-cath (Fig. 4a). Evaluation of differential cell counts demonstrated that neutrophils were the pri-
mary cell type infiltrating into the lungs (Fig. 4b). Hc-cath treatment significantly reduced neutrophil infiltration 
following LPS challenge as well as reducing associated inflammatory cytokines, KC (Fig. 4c) and IL-6 (Fig. 4d).
Hc-cath treatment reduces the bacterial load and inflammatory burden in a mouse model of 
peritoneal infection. We utilised a mouse model of P. aeruginosa peritoneal infection to examine the effect 
of Hc-cath on the bacterial load 6 hr after infection. Mice receiving Hc-cath treatment demonstrated a significant 
reduction in the bacterial load in the spleen (Fig. 5a) and liver (Fig. 5b) but not peritoneal lavage fluid (PLF) 
(Fig. 5c). Assessment of the PLF total cell counts (Fig. 5d) and the release of cytokines KC (Fig. 5e) and IL-6 
(Fig. 5f) revealed a significant increase in the total cells within the peritoneal cavity upon infection. Hc-cath was 
effective at limiting this increase, significantly reducing the total cell counts compared to the infection alone mice 
(Fig. 5d). However, we did not observe a significant reduction in KC (Fig. 5e) or IL-6 levels (Fig. 5f) following 
treatment with Hc-cath, although there was an indication of a downward trend with Hc-Cath in both cases.
The effect Hc-cath treatment on bacterial load, inflammatory cell infiltration and cytokine 
release in a mouse model of respiratory infection. As with the LPS instillation, introduction of P. 
aeruginosa into the lungs resulted in a significant increase in the total number of cells (Fig. 6a) in the lungs of 
which the majority were neutrophils (Fig. 6b). In mice receiving the peptide treatment we observed significant 
reduction in both these counts (Fig. 6a,b). Mice infected i.n. with P. aeruginosa PAO1 exhibited increased bac-
terial load in the BALF and the lungs after 6 hr (Fig. 6c). Pre-treatment with Hc-cath resulted in a significant 
reduction in bacterial load in BALF (Fig. 6c) and the lungs (Fig. 6d). Consistent with the reduction in infiltrating 
cells and bacterial burden there was a significant reduction in the release of inflammatory cytokines IL-6 (Fig. 6e) 
and KC (Fig. 6f) compared to infected mice.
Discussion
With the increased incidence of antimicrobial resistance, there is a real need for new antibiotic agents. In this 
report, we have demonstrated the potent anti-inflammatory and antimicrobial activity of Hc-cath. As well as 
exhibiting limited cytotoxicity, Hc-cath demonstrated the dual ability of dampening inflammation and reducing 
infection.
The physiochemical properties of a peptide can give an indication of their activity and potency. The hydropho-
bic moment of peptides is an indicator of how strongly amphipathic the helix is13 and has been correlated with 
cytotoxic activity14–17 suggesting that the lower hydrophobic moment of Hc-cath which may contribute to the 
limited cytotoxic activity seen in Fig. 2a and has been shown Wei et al.11. Charge and the hydrophobic moment 
Figure 3. Hc-cath exerts an antimicrobial effect against P. aeruginosa and S. aureus and promotes Galleria 
survival. (a) Radial diffusion assay. Agarose gels were inoculated with 100 μl (OD600 − 0.4–0.5) of P. aeruginosa 
or S. aureus as indicated. Plates were challenged with 68.8 µM, 34.4 µM, 17.2 µM or 8.6 µM of Hc-cath and left 
overnight. Plates were stained with Coomassie blue overnight. Image presented representative of 3 independent 
experiments. (b,c) Minimum inhibitory concentration of Hc-cath vs (b) P. aeruginosa or (c) S. aureus as 
calculated from radial diffusion assays. Representative of 3 independent experiments. (d,e) Galleria survival 
over 5 days. Galleria were inoculated with 20 μl of S. aureus (OD600 – 0.25) or P. aeruginosa (OD600 – 0.1 – 
diluted 1 in 1,000,000) in PBS or PBS alone. Galleria received Hc-cath in 20 μl of PBS (68.8 μM) or a second 
injection of PBS. Galleria were incubated at 37 °C and survival was assessed every day. n = 10 galleria per group. 
Survival curves were compared using Kaplan-Meier log rank analysis. *Indicates P < 0.05.
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are also important factors for the antimicrobial activity of membrane active peptides such as these17, again with 
increasing charge and hydrophobic moment conferring greater membrane disruption. Despite this, Hc-cath 
demonstrated an good activity against P. aeruginosa and S. aureus as well improving survival in galleria (Fig. 3e) 
and reducing the bacterial burden in mice (Figs 5 and 6), which may suggest that its high charge is playing a more 
important role. Furthermore, from helical wheel analysis (Fig. 1a) it was found that a section (aa1-18) within the 
Hc-cath sequence formed a near empirical helical wheel, which has been shown to be important for bacterial 
membrane selectivity and disruption as has been observed for GKE2118 and the engineered α-helical peptide 719, 
promoting the antimicrobial activity of the peptide. Together, one could speculate that the near empirical helices 
of Hc-cath promotes greater ability to select bacterial membranes and not to target host cells.
A protective effect of Hc-cath was seen in the models of Galleria Pseudomonas infection (Fig. 3e), highlight-
ing its protective capacity in-vivo. However Hc-cath was not protective in Galleria models of S. aureus (Fig. 3d) 
infection and was generally less effective against S. aureus, which may possibly be due to cleavage by the S. aureus 
protease, aurolysin. Again the Galleria models highlight the lack of toxicity associated with Hc-cath as there was 
no impact of Galleria survival on Hc-cath administration.
Like LL-37, Hc-cath can bind LPS and prevent LPS signalling11,20, providing a probable mechanism for 
Hc-Cath’s anti-inflammatory activity in models of LPS induced inflammation in-vitro. This likely provides 
the mechanism of action of Hc-cath after LPS instillation (Fig. 4a,b) into the lungs, were Hc-cath significantly 
reduced cellular infiltration and cytokine release. However in the context of infection, Hc-cath displayed activity 
against lung relevant pathogens in the radial diffusion assays (Fig. 3a–c) of which activity against P. aeruginosa 
translated to in-vivo models (Figs 5 and 6).
Hc-cath reduced cellular infiltration in the peritoneum and bacterial load in spleen, liver and PLF when 
administered to mice i.p. However, despite a trend in reduction in IL-6 and KC, no significant effect was observed 
with Hc-cath treatment. It is possible that Hc-cath has a systemic antimicrobial effect thereby preventing spread 
to nearby organs. Hc-cath also reduced the recruitment of cells to the peritoneum, suggesting an ability to limit 
the inflammatory response in this compartment, which may be achieved via the improved clearance of bac-
teria as well as increased binding of LPS released by P. aeruginosa. Cath-2, a chicken cathelicidin, was shown 
to kill Escherichia coli in a manner that resulted in a significantly decreased inflammatory response when cul-
tured together with macrophages compared to macrophages cultured with E. coli alone21. As well as improved 
Figure 4. Hc-cath reduces the inflammatory burden in a mouse model of LPS induced acute lung 
inflammation. Age and sex matched female C57Bl6 mice received 100 μl of Hc-cath (137.8 μM) or vehicle 
(H2O) i.p. followed by a second dose after 24 hr. Mice then received 50 μl of LPS (0.4 mg/ml) via intra-tracheal 
instillation. Mice were sacrificed by overdose of rumpon-ketaset at 6 hr and bronchoalveolar lavage fluid was 
collected for analysis. Total cell counts (a) were obtained by enumeration by haemocytometer. Neutrophil (b) 
cell counts were obtained by staining of cytospins with May Grunwald and Geimsa stain and imaged using a 
Leica DM550 light microscope. ImageJ was using to quantify cell numbers. Release of KC (c) and IL-6 (d) into 
the BALF was measured by ELISA n = 3–6 mice per group. Data are presented as mean ± SEM. Means between 
groups (vehicle vs LPS and LPS versus LPS + Hc-cath) were compared by Mann Whitney t-test. *Indicates 
P < 0.05, **p < 0.01, ***p < 0.001.
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Figure 5. Hc-cath reduces the inflammatory burden and bacterial load in a mouse model of peritoneal 
infection. (a–c) Age and sex matched C57Bl6 mice received a 100 μl i.p. injection of Hc-cath (137.8 μM) or 
vehicle (H2O), followed by a second dose at 24 hr. Mice received 100ul PA01 (17.5 × 106 CFU/mouse) via i.p. 
injection. Mice were culled after 6 hr by anaesthetic overdose. Peritoneal lavage fluid, spleen and liver were 
collected for analysis of bacterial load. Livers were homogenised in 2 ml of sterile PBS using a Bertin Precellys 
Evolution bead homogeniser. Spleens were homogenized in 1 ml sterile PBS by a handheld homogenizer. Spleen 
homogenate (a), liver homogenate (b) and peritoneal lavage fluid (c) were serially diluted in sterile PBS and 20ul 
was plated onto cetrimide agar and bacteria allowed to grow overnight before counting. (d–f) Peritoneal lavage 
fluid was collected for analysis of cellular infiltration and cytokine release into the peritoneum. Total cell counts 
(d) were obtained by enumeration by haemocytometer. Release of KC (e) and IL-6 (f) were measured by ELISA. 
n = 7–8 mice per group. Data are presented as mean ± SEM. Means between groups (vehicle vs PAO1 and PAO1 
versus PAO1 + Hc-cath) were compared by Mann Whitney t-test. *Indicates P < 0.05, **p < 0.01, ***p < 0.001.
Figure 6. Intranasal delivery of Hc-cath reduces the cellular infiltration, bacterial load and cytokine release 
in a mouse model of respiratory infection. Age and sex matched C57Bl6 mice received Hc-cath (137.8 μM) in 
30 μl plus 20 μl PBS or 50 μl PBS alone via intranasal delivery. After 24 hr mice received a second dose of 30 μl 
of Hc-cath (137.8 μM) plus 20 μl PAO1 in PBS (3.625–5.5 × 106 per mouse) or PBS alone. Mice were culled at 
6 hr with anaesthetic overdose and BALF was collected analysis of cellular infiltration. (a,b) Total cell counts 
(a) were obtain by enumeration by haemocytometer. Neutrophil (b) cell counts were obtained by staining of 
cytospins with May Grunwald and Geimsa stain and imaged using a Leica DM550 light microscope. Image J 
was using to quantify cell numbers. (c,d) BALF and lung homogenate were analysed for bacterial load. BALF 
was analysed for the release of IL-6 (e) and KC (f) by ELISA. ELISA. n = 7–8 mice per group. Data are presented 
as mean ± SEM. Means between groups (vehicle vs PAO1 and PAO1 versus PAO1 + Hc-cath) were compared by 
Mann Whitney t-test. *Indicates P < 0.05, **p < 0.01, ***p < 0.001.
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anti-microbial activity stability and clearance are also worth considering as a factor contributing to the actvtiy 
of Hc-cath. Peptides tend to have a short half-life in vivo with enzymatic cleavage occurring in blood, liver and 
kidneys and peptides are excreted via the renal system22. The mechanism of clearance of Hc-cath is unknown, but 
this peptide is stable in serum for up to 6 hr11. Cleavage of LL-37 by neutrophil elastase and cysteinyl cathepsin 
proteases in the chronically inflamed lung has previously been shown10 and is an important consideration of any 
peptide therapeutic. The previously demonstrated stability of Hc-cath11 and the activity of Hc-cath with the more 
physiologically relevant environments within the mouse models highlight Hc-cath’s stability and activity.
Following i.n. administration, Hc-cath reduced the bacterial burden, neutrophil infiltration into the lungs and 
cytokine release. Again, this may relate to enhanced stability and greater activity of Hc-cath in the airways. Bals et al.23, 
demonstrated an antimicrobial effect following administration of an LL-37 over-expressing plasmid to the rodent 
lungs. This results appears to be similar to what we have demonstrated with Hc-cath. Others found that i.n. deliv-
ery of LL-37 with P. aeruginosa increased neutrophil infiltration after 6 hr, which was associated with a reduction 
in the bacterial load in the lungs24. However, in contrast, no increase in neutrophil infiltration was seen after 
Hc-Cath administration to the lungs during infection. This data would suggest Hc-cath is not chemotactic for 
neutrophils and that the antimicrobial activity of Hc-cath is via a direct action of the peptide on the bacteria. This 
is important to consider as neutrophils can be mediators of pathology in conditions such as CF, where reducing 
bacteria load without inducing further neutrophil infiltration may be of benefit.
Our studies suggest that Hc-cath has a potent antimicrobial effect against P. aeruginosa within the mouse lung. 
Importantly, as demonstrated in the peritoneal infection model, the antimicrobial activity of the peptide does not 
result in an inflammatory response due to the release of immunogenic components from dying bacteria. Cath 2 
from chickens also does not cause inflammation from dying bacteria whereas such a side-effect was observed in 
mice treated with gentamicin25.
In conclusion, we have demonstrated the potential for Hc-cath to diminish infection and inflammation in 
pre-clinical mouse models. Given the need for new antimicrobials, Hc-cath is a potentially promising option to 
take forward into development as a therapeutic to combat infection.
Materials and Methods
Peptides. Hc-cath was synthesised by GL Biochem (Shanghai, China), respectively.
Sequence and physiochemical properties of Hc-cath. Helical wheel projections were generated using 
HeliQuest server accessible via http://heliquest.ipmc.cnrs.fr. Primary amino acid sequences were submitted to the 
server and analysis parameters set to alpha helical with 18 amino acid analysis windows.
THP-1 cell culture. Human acute monocytic leukemia cells (THP-1) were obtained from the American 
Type Culture Collection (ATCC, Manassas, USA) and were maintained in RPMI 1640 media (ThermoFisher 
Scientific, UK) supplemented with 10% heat-inactivated FCS (ThermoFisher Scientific, UK) and 1% Penicillin/
Streptomycin (ThermoFisher Scientific, UK). For differentiation, phorbol 12-myristate 13-acetate (100 ng/ml; 
Sigma-Aldrich, Dorset, UK) was added to THP-1 cell suspension and cells were incubated for 72 hr period fol-
lowed by 24 hr rest in fresh media. For LPS stimulation experiments, THP-1 macrophages were stimulated with P. 
aeruginosa LPS alone (100 ng/ml; Serotype 10, Source strain ATCC 27316; Sigma-Aldrich) or LPS in combination 
with peptide and incubated for 16 hr. Supernatants were collected for analysis by ELISA. For cell viability assays, 
THP-1 macrophages were incubated with Fluorofire-Blue ProViaTox kit (Molecutools, Dublin, Ireland) as per 
manufacturer’s instructions. Staurosporine (Sigma Aldrich, 10 mM) was used as positive control.
Radial diffusion assays (RDA). Radial diffusion assays (RDA) for Pseudomonas aeruginosa ATCC 27853 
and Staphylococcus aureus ATCC 25923 were performed as previously described26.
Galleria mellonella model of microbial infection. S. aureus and P. aeruginosa were grown aerobically to 
mid-logarithmic phase in Mueller Hinton Broth (Biokar Diagnostics, Beauvais, France) at 37 °C. The OD600 was 
adjusted to in-house optimised values of OD600 = 0.25 in sterile ice cold PBS (ThermoFisher Scientific, UK) for 
S. aureus and OD600 = 0.1, which was further diluted 1:1,000,000 in sterile PBS, for P. aeruginosa. Peptide in PBS 
(68.8 μM) or PBS alone was injected into the rear left proleg of each Galleria (Waxworms, UK), followed by 20 μl 
bacterial suspension via the rear right proleg. Uninfected controls received 2 × 20 μl injections of peptide or PBS. 
G. mellonella were incubated at 37 °C for 5 days and survival evaluated by onset of melanisation and movement 
in response to stimulus. Whole wax moth larvae were homogenised in 1 ml sterile PBS plated on blood agar after 
dilution for colony forming unit (CFU) viable counts.
Mouse models of acute lung inflammation and infection. All experimentation was carried out in 
accordance with the Animal (Scientific Procedures) Act 1986 and current guidelines approved by the Queen’s 
University Ethical Review Committee. C57Bl6 mice (10–12 weeks of age) were used in all experiments and were 
purchased from Charles Rivers Laboratories (UK).
Mouse model of endotoxin-induced acute lung inflammation. Mice were administered Hc-Cath (137.8 μM) or 
vehicle (H20) intraperitoneally (i.p.) every 24 hr for 2 days and challenged with Pseudomonas LPS (0.4 mg/ml; 
Sigma Aldrich) or saline alone intratacheally (i.t.) as previously described27. The mice were sacrificed 6 hr later, 
bronchoalveolar lavage fluid (BALF) collected for ELISAs and cell counts. Total cells counts were performed using 
a haemocytometer. Differential cell counts were enumerated (at least 400 cells per slide) on cytospins stained with 
May-Grünwald Giemsa (VWR, UK) imaged using a Leica DM55 brightfield microscope (Leica Microsystems, UK).
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Intraperitoneal Pseudomonas aeruginosa infection. Mice were treated with Hc-cath (137.8 μM) or vehicle (H2O) 
as outlined above and challenged with P. aeruginosa (PA01, OD600 = 0.5 per mouse) or PBS alone delivered i.p. 
Mice were sacrificed 6 hr later and the peritoneal cavity was washed with 5 ml PBS and peritoneal lavage fluid 
(PLF) collected and used for the analysis for total cell counts and ELISA. Spleens were homogenised in 1 ml ster-
ile PBS and livers were homogenised in 2 ml of sterile PBS for CFU counts. PLF, spleen homogenates and liver 
homogenates were diluted and plated on cetrimide agar for CFU counts.
Respiratory Pseudomonas aeruginosa infection. Mice received Hc-cath (137.8 μM) in 30 μl plus 20 μl PBS or 50 μl 
PBS alone via intranasal delivery. After 24 hr mice received a second dose of 30 μl of Hc-cath (137.8 μM) plus 20 μl 
PAO1 in PBS (OD. 0.5) or PBS alone. All i.n. instillations were carried out during anaesthetisation using isoflu-
rane. Mice were sacrificed 6 hr later and BALF collected and processed as described above. Lungs and spleen were 
collected, homogenised in 1 ml of sterile PBS, and plated on cetrimide agar for CFU counts.
ELISAs. Levels of IL-6 (Thermo Fisher Scientific, UK) and IL-8 (Biolegend, London, UK) in cell-free THP-1 
macrophage supernatants and KC (R&D Systems, Abingdon, UK) and IL-6 (Thermo Fisher Scientific, UK) in 
cell-free BALF were quantified by ELISA as per manufacturer’s instructions.
Statistics. All data were analysed using GraphPad Prism 5.0 (GraphPad Software Inc., San Diego, CA). Data 
are presented as mean ± SEM. Means were compared by Mann Whitney t-test where vehicle/untreated or drug 
(Hc-cath) group data was compared to LPS or infection (PAO1) data. P < 0.05 was accepted to indicate sta-
tistical significance. Survival curves were compared using Kaplan-Meier log rank analysis. *Indicates P < 0.05, 
**p < 0.01, ***p < 0.001.
Data Availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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